tiprankstipranks
aTyr Pharma (LIFE)
NASDAQ:LIFE

aTyr Pharma (LIFE) Technical Analysis

1,772 Followers

Technical Sentiment

Overall Consensus
Buy
14Bullish
5Neutral
3Bearish
Technical Analysis Consensus
Buy
4Bullish
5Neutral
1Bearish
Moving Average Consensus
Strong Buy
10Bullish
0Neutral
2Bearish
aTyr Pharma’s (LIFE) Moving Averages Convergence Divergence (MACD) indicator is 0.02, suggesting aTyr Pharma is a Buy.
aTyr Pharma’s (LIFE) 20-Day exponential moving average is 1.80, while aTyr Pharma’s (LIFE) share price is $1.9, making it a Buy.
aTyr Pharma’s (LIFE) 50-Day exponential moving average is 1.77, while aTyr Pharma’s (LIFE) share price is $1.9, making it a Buy.

aTyr Pharma (LIFE) Pivot Points

Jul 19, 2024, 09:23 AM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
1.70
1.76
1.83
1.89
1.96
2.02
2.09
Fibonacci
1.76
1.81
1.84
1.89
1.94
1.97
2.02
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

aTyr Pharma (LIFE) Moving Averages

Jul 19, 2024, 09:23 AM
Period
Simple
Exponential
MA5
1.81Buy
1.82Sell
MA10
1.80Buy
1.82Buy
MA20
1.82Sell
1.80Buy
MA50
1.76Buy
1.77Buy
MA100
1.76Buy
1.74Buy
MA200
1.59Buy
1.70Buy
aTyr Pharma’s (LIFE) 10-Day exponential moving average is 1.82, while aTyr Pharma’s (LIFE) share price is $1.9, making it a Buy.
aTyr Pharma’s (LIFE) 100-Day exponential moving average is 1.74, while aTyr Pharma’s (LIFE) share price is $1.9, making it a Buy.
aTyr Pharma’s (LIFE) stock price is $1.9 and aTyr Pharma’s (LIFE) 50-day simple moving average is 1.76, creating a Buy signal.
aTyr Pharma’s (LIFE) stock price is $1.9 and aTyr Pharma’s (LIFE) 100-day simple moving average is 1.76, creating a Buy signal.
aTyr Pharma’s (LIFE) stock price is $1.9 and aTyr Pharma’s (LIFE) 200-day simple moving average is 1.59, creating a Buy signal.

aTyr Pharma (LIFE) Technical Indicators

Jul 19, 2024, 09:23 AM
Name
Value
Implied Action
RSI (14)
51.90
Neutral
STOCH (9,6)
61.82
Neutral
STOCHRSI (14)
46.97
Neutral
MACD (12,26)
0.02
Buy
ADX (14)
16.26
Buy
Williams %R
-61.36
Buy
CCI (14)
5.57
Neutral
ATR (14)
0.12
-
Ultimate Oscillator
45.79
Neutral
ROC
-5.21
Sell
aTyr Pharma’s (LIFE) Relative Strength Index (RSI) is 51.90, creating a Neutral signal.
aTyr Pharma’s (LIFE) Trend Strength Indicator (ADX) is 16.26, creating a Buy signal.
aTyr Pharma’s (LIFE) Commodity Channel Index (CCI) is 5.57, creating a Neutral signal.
aTyr Pharma’s (LIFE) Price Rate of Change (ROC) is -5.21, creating a Sell signal.

FAQ

Is LIFE a Buy, Hold, or Sell?
Based on LIFE’s technical indicators, LIFE is a Buy.
    What is LIFE’s RSI (14)?
    LIFE’s RSI (14) is 51.90, which suggests LIFE is a Neutral.
      What is LIFE’s MACD?
      LIFE’s MACD is 0.02, which suggests LIFE is a Buy.
        What is LIFE’s 5-day moving average?
        LIFE’s 5-day moving average is 1.81, which suggests LIFE is a Buy.
          What is LIFE’s 20-day moving average?
          LIFE 20-day moving average is 1.82, which suggests LIFE is a Sell.
            What is LIFE’s 50-day moving average?
            LIFE’s 50-day moving average is 1.76, which suggests LIFE is a Buy.
              What is LIFE’s 200-day moving average?
              LIFE’s 200-day moving average is 1.59, which suggests LIFE is a Buy.
                What is LIFE’s Williams % R (14)?
                LIFE’s Williams % R (14) is -61.36, which suggests LIFE is a Buy.
                  What is LIFE’s CCI (14)?
                  LIFE’s CCI (14) is 5.57, which suggests LIFE is a Neutral.
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis